Article ; Online: Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections.
Clinical lymphoma, myeloma & leukemia
2021 Volume 21, Issue 10, Page(s) e810–e816
Abstract: ... We provide a follow-up report of the case along with a literature review of immunocompromised lymphoma ... We found 19 case reports of immunocompromised lymphoma patients with prolonged COVID-19 infections ... Immunocompromised lymphoma patients are at risk of a prolonged disease course of COVID-19, and convalescent plasma ...
| Abstract | Background: We previously reported elsewhere of a follicular lymphoma patient suffering from persistent COVID-19 pneumonia that was still ongoing at 2 months after onset. Materials and methods: We provide a follow-up report of the case along with a literature review of immunocompromised lymphoma patients experiencing prolonged COVID-19 infections. Results: Although requiring a full 1 year, the presented case eventually achieved spontaneous resolution of COVID-19 pneumonia. Anti-SARS-CoV-2 antibodies could not be detected throughout the disease course, but COVID-19-directed T-cell response was found to be intact. The patient also developed secondary immune thrombocytopenia subsequent to COVID-19 pneumonia. We found 19 case reports of immunocompromised lymphoma patients with prolonged COVID-19 infections in the literature. All 5 patients who died did not receive convalescent plasma therapy, whereas resolution of COVID-19 infection was achieved in 8 out of 9 patients who received convalescent plasma therapy. Conclusions: We demonstrate through the presented case that while time-consuming, resolution of COVID-19 infections may be achieved without aid from humoral immunity if cellular immunity is intact. Immunocompromised lymphoma patients are at risk of a prolonged disease course of COVID-19, and convalescent plasma therapy may be a promising approach in such patients. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Antineoplastic Agents, Immunological/therapeutic use ; COVID-19/immunology ; COVID-19/virology ; Female ; Follow-Up Studies ; Humans ; Immunocompromised Host/immunology ; Lymphoma, Follicular/complications ; Lymphoma, Follicular/drug therapy ; Lymphoma, Follicular/immunology ; Maintenance Chemotherapy/methods ; Middle Aged ; Pneumonia/complications ; Pneumonia/immunology ; Pneumonia/virology ; Remission, Spontaneous ; Rituximab/therapeutic use ; SARS-CoV-2/immunology ; SARS-CoV-2/physiology ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; Thrombocytopenia/complications ; Thrombocytopenia/immunology | |||||
| Chemical Substances | Antineoplastic Agents, Immunological ; Rituximab (4F4X42SYQ6) | |||||
| Language | English | |||||
| Publishing date | 2021-07-18 | |||||
| Publishing country | United States | |||||
| Document type | Case Reports ; Journal Article ; Review | |||||
| ZDB-ID | 2540992-X | |||||
| ISSN | 2152-2669 ; 2152-2650 | |||||
| ISSN (online) | 2152-2669 | |||||
| ISSN | 2152-2650 | |||||
| DOI | 10.1016/j.clml.2021.07.004 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5903: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.